Legend Biotech Corp stock (US52490G1022): LB2501 trial data fuel sharp Nasdaq move
03.06.2026 - 08:28:40 | ad-hoc-news.de
Legend Biotech shares on the Nasdaq Stock Market traded significantly higher this week after the United States-based cell therapy group reported early Phase 1 data for its in vivo CAR-T candidate LB2501 in relapsed or refractory B-cell non-Hodgkin lymphoma, drawing attention to the companys oncology pipeline according to a Form 6-K filed with the U.S. Securities and Exchange Commission on 06/02/2026 and summarized by Stock Titan as of 06/02/2026.
The company, which is headquartered in Somerset, New Jersey, said in the U.S. filing that LB2501 achieved a 100 percent objective response rate at the higher dose level in a 12-patient cohort, with a complete response rate of 83.3 percent at that dose and no dose-limiting toxicities or serious adverse events reported as of the 04/01/2026 data cutoff, underscoring the prominence of the American market and the Nasdaq listing for funding its clinical programs.
As of: 06/03/2026
By the editorial team - specialized in equity coverage.
At a glance
- Name: Legend Biotech Corp
- Sector/industry: Biotechnology - cell and gene therapy
- Headquarters/country: Somerset, United States
- Core markets: United States, Europe, China
- Key revenue drivers: Commercial CAR-T therapies and partnered oncology products
- Home exchange/listing venue: Nasdaq (LEGN)
- Trading currency: USD
Legend Biotech Corp: core business model
Legend Biotech focuses on developing and commercializing cell-based cancer therapies, with value creation largely tied to the clinical progress and uptake of its CAR-T pipeline and partnered hematology-oncology products.
Legend Biotech Corp in peer comparison
In the cell therapy space, Legend Biotech is often mentioned alongside names such as Gilead Sciences and Bristol Myers Squibb, both of which market approved CAR-T therapies targeting hematologic malignancies and report multi-billion-dollar annual revenue contributions from these franchises as of their 2025 results according to company disclosures cited by major financial media as of early 2026. Gilead, for example, has reported strong sales growth for its Yescarta and Tecartus CAR-T treatments in the United States and Europe in its 2025 filings, while Bristol Myers Squibb has highlighted continued demand for Abecma and Breyanzi across major oncology centers based on its 2025 annual report figures, providing a reference frame for how Legend Biotechs LB2501 program could be assessed by investors if it eventually reaches commercialization.
Read more
Additional news and developments on the stock can be explored via the linked overview pages.
Sentiment and reactions on Legend Biotech Corp
Following the strong LB2501 Phase 1 data and the associated stock price reaction on Nasdaq, social media and video platforms have featured active discussion from traders and biotech-focused commentators on the potential implications for Legend Biotechs broader CAR-T franchise.
Conclusion
The early LB2501 Phase 1 results described in the U.S. Form 6-K show high response rates and a favorable safety profile in a small relapsed or refractory B-cell non-Hodgkin lymphoma cohort, which has coincided with an elevated trading interest in Legend Biotech shares on Nasdaq. When viewed against larger CAR-T peers such as Gilead Sciences and Bristol Myers Squibb, the data help frame Legend Biotechs position within the competitive cell therapy landscape without yet resolving questions on long-term durability, regulatory paths, or eventual commercial scale.
Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.
